A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT07690371 · RECRUITING

Trial details

NCT number: NCT07690371
Sponsor: Nektar Therapeutics
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Moderate-to-Severe Atopic Dermatitis

Start date: 2026-06-29
Primary completion: 2028-05-01
Enrollment: 510

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.